By Dr. Sunni Patel, medeuronet clinical scientist With final discussions taking place...November 19, 2015
“ One company, with three areas of expertise,
each with dedicated leadership & resources –
delivering a continuum of solutions.”
“ We share your drive to make things better.
So we built a better way to get your medtech innovation
to the right people in Europe.”
We guide your medtech innovation through the entire medtech lifecycle.
Whether an established or a start-up company, you need one partner that can guide you.
medeuronet played a part in two of the biggest exits in ophthalmology in the past 10 years – WaveTec Vision Systems and IntraLase.
The path is the same for any medical device. We bring focus, consistency and efficiency to the commercialization process.
A controlled process. The best way to change a market is to correctly target, prove your value, then expand.
We get your technology into the right hands at the right time, with expert training and support.
Pegged at EUR 55 billion+, the EU medical device market is second only to that of the United States, with a shorter regulatory process that allows for market introduction to test product interest and market adoption.
Europe is not one market – it’s a collection of culturally diverse markets, each with its own regulatory requirements and commercialization process. You also face a changing regulatory landscape, increasing reimbursement and pricing pressures in a challenging environment.
“ medeuronet played a part
in two of the biggest exits in ophthalmology in the past 10 years –
WaveTec and IntraLase. ”
WaveTec was acquired by Alcon/Novartis in October 2014. medeuronet worked with WaveTec from 2007, assisting with communication and market launch to EU commercial introduction and acquisition.
IntraLase was acquired by Abbott for almost a billion dollars; here medeuronet’s medical communication team helped power the marketing story that saw the IntraLase Femtosecond Laser change the refractive surgery laser market.
With TearLab Corporation, medeuronet worked with the company to set-up TearLab’s groundbreaking Core Validation Study – a 6-center European study that demonstrated the benefit of an objective test for dry eye disease.
medeuronet’s network provides our clients with robust expertise in the key areas of reimbursement, regulatory and clinical study management along with a country commercial network that ensures consistent market introduction.
The latest news from medeuronet